Rational Vaccines and Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Announce Collaboration to Develop Herpes Vaccines in China
30 Oct 2023
VaccineClinical StudyEmergency Use Authorization
The partnership will further therapeutic and prophylactic vaccine development for the Chinese market and beyond.
WOBURN, Ma. and SHENZHEN, China, Oct. 30, 2023 /PRNewswire/ -- Rational Vaccines (RVx) and Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (MH) announced they have reached an agreement to jointly develop, manufacture, and commercialize live vaccines against herpes simplex viruses (HSV-1 and HSV-2).
"For over 40 years there have been a multitude of failed attempts to create a herpes vaccine using recombinant protein subunit-based vaccines. The data shows this approach will not work for HSV," said Agustin Fernandez III, CEO and Founder at RVx. "We are confident a live attenuated vaccine is the only way to combat and prevent herpetic disease. We are excited that the top vaccine experts in China share our vision. It is an honor to tackle this mission with our partners at MH."
Professor Frank Zhuang, Vice Chairman of Virology at the Chinese Medical Association, said, "The Chinese population, like many globally, suffers from the spread of herpes and lacks awareness of the associated risks. There is no pharmaceutical or TCM solution to herpes and these vaccines represent an invaluable new solution to a broad population."
The vaccines will be advanced in China using RVx's proprietary virus mutants. The live HSV-2 viruses used in the vaccines are engineered to be replication-competent and are unable to establish latency in the nervous system. The immune system responds by attacking the weakened virus and eliminating it from the body. The targeted immune response elicited by RVx vaccines has the potential to also defend against viral reactivation in patients who are already infected with either HSV-1 or HSV-2
These viruses have received support from the US National Institute of Health (NIH) and the vaccines have received the coveted Innovative Access and License Pathway (ILAP) designation by MHRA, to accelerate development and approval in the United Kingdom.
Zhuang said MH was impressed with the technology and the associated data. "We are convinced these vaccines will greatly improve the major public health issue of herpetic diseases, so often misunderstood and neglected," he said.
While several vaccines have been evaluated for preventing and treating HSV infections, none have received FDA approval. RVx aims to be the first.
About Rational Vaccines
Rational Vaccines develops rationally engineered, live attenuated viral immunotherapeutic and prophylactic vaccine candidates, focused on combating herpetic diseases. Led by a team of world-renowned scientists and aligning to regulatory guidelines, we believe our technology will revolutionize the treatment, prevention, and diagnosis of herpes and herpes-related diseases.
For more information go to https://rationalvaccines.com. Media inquiries can be directed to [email protected].
Shenzhen Mellow Hope Pharm Industrial Co., Ltd. is a leading vaccine supplier in P.R.C. and the #1 Chinese Vaccine Exporter before the Covid pandemic.
For more information go to https://english.mellowhope.com/ Media inquiries can be directed to [email protected].
SOURCE Rational Vaccines
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.